Adlai Nortye Ltd. filings document foreign private issuer reports for a clinical-stage oncology biotechnology company whose securities trade as American depositary shares. The company’s Form 6-K reports include pipeline disclosures for AN9025, AN4035, AN8025, AN4005 and AN0025; clinical and regulatory updates; unaudited financial results; corporate presentations; and material agreements.
ANL filings also record capital-structure matters, including private-placement securities purchase agreements and ADS-to-Class A ordinary share references, as well as shareholder meeting materials, proxy cards, board and committee changes, executive appointments, and the adoption of a share incentive plan.
Adlai Nortye Group Ltd. (ANL) announced that an AN4035 abstract was selected for an oral presentation at the 38th EORTC-NCI-AACR Symposium in Barcelona, scheduled for November 18–20, 2026. Dr. Archie Tse, President and Head of Research & Development, is scheduled to present on November 19, 2026, at 8:00 a.m. Central European Time. The presentation will include translational and combination data, including evaluation with EGFR blockade, from the ongoing Phase I study.
AN4035 is a CEACAM5-targeting ADC carrying a proprietary pan-RAS(ON) inhibitor payload. Adlai Nortye is evaluating it in patients with CEACAM5-enriched RAS-addicted solid tumors in a global Phase I trial in Australia, the U.S. and China.
Adlai Nortye Group Ltd. (ANL) entered into clinical trial collaboration and supply agreements with Eli Lilly and Company and Merck KGaA, Darmstadt, Germany, for cetuximab in its ongoing global Phase I trial of AN4035. The trial evaluates AN4035 as monotherapy and in combination with cetuximab in patients with CEACAM5-enriched, RAS-addicted solid tumors, assessing safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy.
Lilly will supply cetuximab at no cost for U.S. trial sites, and Merck KGaA will supply it at no cost for sites in Australia and China. The monotherapy and combination arms will start on a staggered timeline.
Adlai Nortye Group Ltd. (ANL) director Ping Ji reported direct sales of American Depository shares: 5,000 at $16.03 per share and 5,000 at $15.95 on September 30, 2026, and 214 at $15.77 per share on September 29, 2026. The Rule 10b5-1 checkbox was unchecked.
Adlai Nortye Group Ltd. announced the appointment of Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Liu brings nearly a decade of equity research experience focused on biotechnology and oncology.
The company describes its pipeline as covering two key therapeutic areas: precision RAS pathway-targeted therapies, including oral pan-RAS(ON) inhibitor AN9025 and CEACAM5-targeting ADC AN4035; and next-generation PD-1/L1 pathway-modulating immunotherapies, including AN8025, a fusion protein that modulates T cells and antigen-presenting cells.
Adlai Nortye Group Ltd. (ANL) reported that shareholders passed all resolutions presented at its September 30, 2026 extraordinary general meeting. Holders of 40,433,365 ordinary shares attended in person or by proxy, constituting a quorum. A total of 193,193,810 ordinary shares were issued and outstanding and entitled to vote as of the August 28, 2026 record date. The full text of the resolutions was included in the company’s August 26, 2026 meeting notice.
Ji Ping, a director of Adlai Nortye Group Ltd. (ANL), sold 5,000 American Depository shares at $16.63 per share on September 22, 2026. His reported direct holdings after the sale were 131,667 American Depository shares. No Rule 10b5-1 plan is reported.
Adlai Nortye Group Ltd. (ANL) director Ji Ping filed a notice of proposed sale under Rule 144 covering up to 80,000 American Depository Shares (ADS) of Adlai Nortye through Tiger Brokers (Singapore) Pte. Ltd. on NASDAQ, with an approximate sale date of September 29, 2026 and an aggregate market value of $1,222,400.
The filing references 176,203,810 Class A ordinary shares outstanding for Rule 144 calculations and notes that each ADS represents three Class A ordinary shares. The ADS position to be sold was acquired on June 10, 2026 via a distribution from The PECO Innovation Trust.
Adlai Nortye Group Ltd. (ANL) filed a post-effective amendment to its Form F-3 shelf to register up to US$600,000,000 of mixed securities and the resale of up to 98,577,627 Class A Ordinary Shares (32,859,209 ADSs) by selling shareholders from 2026 private placements.
The amendment reflects the company’s continuation from the Cayman Islands to Singapore, with ADSs continuing to trade on Nasdaq under “ANL.” Adlai Nortye is a clinical-stage oncology company with RAS-targeted therapies and next-generation immuno-oncology assets, supported by collaborations with partners such as ASK Pharm, Biotime, WuXi Biologics, and Eisai.
Adlai Nortye Group Ltd. (ANL), a clinical-stage oncology company, reported that the first patient has been dosed with its antibody-drug conjugate AN4035 in Australia, initiating a global Phase I trial in patients with CEACAM5-enriched, RAS-addicted solid tumors.
The company also received a U.S. FDA “Study-May-Proceed” letter clearing its IND for AN4035, enabling expansion of the trial into the United States, and plans to file an additional IND for AN4035 with China’s NMPA. Adlai Nortye aims to report full Phase Ia data in the second half of 2027.